Marshall Wace LLP Cuts Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS)

Marshall Wace LLP reduced its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 92.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after selling 123,576 shares during the period. Marshall Wace LLP’s holdings in Pyxis Oncology were worth $33,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of PYXS. SG Americas Securities LLC acquired a new stake in Pyxis Oncology during the 1st quarter worth approximately $59,000. Susquehanna Fundamental Investments LLC purchased a new stake in Pyxis Oncology during the 1st quarter worth $351,000. Vanguard Group Inc. lifted its holdings in Pyxis Oncology by 7.3% in the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after buying an additional 94,740 shares in the last quarter. StemPoint Capital LP acquired a new stake in shares of Pyxis Oncology during the first quarter valued at about $7,643,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Pyxis Oncology during the first quarter worth about $7,082,000. 39.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PYXS shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, Stifel Nicolaus started coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $9.00.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $3.19 on Tuesday. Pyxis Oncology, Inc. has a 52-week low of $1.35 and a 52-week high of $6.85. The stock has a market cap of $187.85 million, a PE ratio of -2.35 and a beta of 1.27. The firm’s 50 day moving average price is $3.53 and its two-hundred day moving average price is $3.81.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. As a group, sell-side analysts predict that Pyxis Oncology, Inc. will post -1.07 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.